In this episode of The Purposeful Strategist, Belden Menkus speaks with Juho Jalkanen, CEO of Faron, a biotechnology company on a mission to bring cutting-edge immunotherapy to as many patients as possible, currently focused on difficult-to-treat cancers.
In their conversation, they discuss:
How immunotherapy uses the patient's own immune system to attack disease, and why that makes it such a promising treatment.
Faron's business strategy, rooted in absorbing the financial risk of scientific research, and how they keep pharmaceutical partners updated as they "de-risk" the product through clinical trials.
Why Faron's steadfast commitment to research, rather than shedding it for a safer business case, as many biotech companies do, is its greatest commercial asset.
Juho's own path from vascular surgeon to CEO, rooted in his desire to help as many patients as possible.
Belden Menkus is the Managing Director of Menkus & Associates, the strategy firm for businesses with a broader purpose. His McKinsey training combined with more than 30 years working at Board and ExCo level gives him both the analytical rigour and the insight that complex, high-stakes leadership situations demand.
Belden hosts The Purposeful Strategist, a weekly podcast. It explores how senior leaders bring purpose to life through strategy.
Podden och tillhörande omslagsbild på den här sidan tillhör
Belden Menkus. Innehållet i podden är skapat av Belden Menkus och inte av,
eller tillsammans med, Poddtoppen.
